These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 26243202)

  • 1. American Association of Cancer Research Showcases Immunotherapy Advances.
    Brower V
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
    [No Abstract]   [Full Text] [Related]  

  • 2. PD-1-targeted immunotherapy: recent clinical findings.
    Brahmer JR
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
    [No Abstract]   [Full Text] [Related]  

  • 3. Challenges to Biomarker Testing for PD-1/PD-L1 Checkpoint Inhibitors for Lung Cancer.
    Cagle PT; Bernicker EH
    Arch Pathol Lab Med; 2015 Dec; 139(12):1477-8. PubMed ID: 26619015
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical Trials of PD-1 and PD-L1 inhibitors in NSCLC.
    Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):14-6. PubMed ID: 24852398
    [No Abstract]   [Full Text] [Related]  

  • 5. Immuno-oncology moves beyond PD-1.
    Sheridan C
    Nat Biotechnol; 2015 Jul; 33(7):673-5. PubMed ID: 26153987
    [No Abstract]   [Full Text] [Related]  

  • 6. PD-1 Blockers.
    Wolchok JD
    Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immuno-oncology drugs jostle for first-line setting.
    Mullard A
    Nat Rev Drug Discov; 2016 Nov; 15(11):738. PubMed ID: 27807351
    [No Abstract]   [Full Text] [Related]  

  • 8. Programmed death protein 1 inhibitors making inroads in multiple cancers.
    Brower V
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
    [No Abstract]   [Full Text] [Related]  

  • 9. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
    Hersey P; Gowrishankar K
    Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
    Socinski MA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune modulation in cancer with antibodies.
    Page DB; Postow MA; Callahan MK; Allison JP; Wolchok JD
    Annu Rev Med; 2014; 65():185-202. PubMed ID: 24188664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-Line Immune Therapy-Implications for Pathologists.
    Miller RA; Cagle PT; Bernicker EH
    Arch Pathol Lab Med; 2016 Aug; 140(8):739-40. PubMed ID: 27472228
    [No Abstract]   [Full Text] [Related]  

  • 14. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
    Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.
    Lee J; Kefford R; Carlino M
    Immunotherapy; 2016 Jun; 8(6):733-46. PubMed ID: 27197541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond ipilimumab: new approaches target the immunological synapse.
    Garber K
    J Natl Cancer Inst; 2011 Jul; 103(14):1079-82. PubMed ID: 21737695
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
    Robert C; Soria JC; Eggermont AM
    Eur J Cancer; 2013 Sep; 49(14):2968-71. PubMed ID: 23907003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression as a potential predictive biomarker.
    Fusi A; Festino L; Botti G; Masucci G; Melero I; Lorigan P; Ascierto PA
    Lancet Oncol; 2015 Oct; 16(13):1285-7. PubMed ID: 26433815
    [No Abstract]   [Full Text] [Related]  

  • 19. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
    Lote H; Cafferkey C; Chau I
    Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising early results for immunotherapy-antiangiogenesis combination.
    Garber K
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421345
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.